Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 1 of 35 PageID# 30303
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 1 of 35 PagelD# 30303
`
`EXHIBIT 1
`EXHIBIT 1
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 1 of 35 PagelD# 30303
`
`EXHIBIT 1
`EXHIBIT 1
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 2 of 35 PageID# 30304
`
`UPDATES FROM FDA’S
`CENTER FOR TOBACCO PRODUCTS
`
`Mitch Zeller, J.D.
`Director, FDA Center for Tobacco Products
`
`Disclaimer: This is not a formal dissemination of information by FDA and does not represent Agency position or policy.
`
`October 27, 2021
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 3 of 35 PageID# 30305
`
`AGENDA
`
`• Programmatic Updates
`- Latest Data on Youth E-Cigarette Use
`- Product Review: Progress on Tobacco Product Application
`Review
`- Compliance and Enforcement
`- Rules and Guidances
`- Public Education Campaigns
`• A New Challenge: Synthetic Nicotine
`• Q&A
`
`1
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 4 of 35 PageID# 30306
`
`LATEST DATA ON YOUTH E-CIGARETTE USE
`
`2
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 5 of 35 PageID# 30307
`
`2021 NATIONAL YOUTH TOBACCO SURVEY FINDINGS
`
`On Oct. 1, FDA and CDC released findings from the 2021 National Youth Tobacco Survey
`(NYTS) on e-cigarette use among middle and high school students
`
`3
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 6 of 35 PageID# 30308
`
`METHODOLOGICAL CHANGES DUE TO COVID-19
`
`• This NYTS—administered Jan. 18 through May 21, 2021—was the first to be fully
`conducted during the COVID-19 pandemic
`
`• Data were collected using an online survey to allow eligible students to participate in the
`classroom, at home, or in some other place to account for various school settings during
`this time
`
`• Different from years before the pandemic, when the survey was conducted exclusively
`in the classroom at school
`
`• Because of the changes in the way the survey was conducted this year, 2021 NYTS
`results cannot be compared to findings from previous surveys
`
`4
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 7 of 35 PageID# 30309
`
`2021 NYTS KEY FINDINGS
`
`5
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 8 of 35 PageID# 30310
`
`FLAVORED ENDS PRODUCTS AND YOUTH USE
`
`• Our concern about youth use of e-cigarettes—especially those the data show are most
`appealing to, and used by, youth—remains high
`
`• We continue to address youth use of e-cigarettes through:
`
`– Premarket review of tobacco product applications
`
`– Compliance and enforcement efforts
`
`– Public education campaigns
`
`6
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 9 of 35 PageID# 30311
`
`PRODUCT REVIEW: PROGRESS ON TOBACCO PRODUCT
`APPLICATION REVIEW
`
`7
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 10 of 35 PageID# 30312
`
`FDA’S TOBACCO AUTHORITIES
`
`• The Tobacco Control Act—passed in 2009—gave FDA immediate authority to regulate
`cigarettes, smokeless tobacco, cigarette tobacco, and roll-your-own tobacco
`
`• When FDA’s “Deeming Rule” went into effect on Aug. 8, 2016, FDA’s authority expanded
`to cover e-cigarettes and all other electronic nicotine delivery systems (ENDS), cigars, pipe
`tobacco, nicotine gels, and hookah tobacco
`
`• As a result, deemed products are now subject to the same requirements in the Tobacco
`Control Act that apply to cigarettes, smokeless tobacco, cigarette tobacco, and roll-your-
`own tobacco
`
`– This includes the requirement that a new tobacco product must receive premarket
`authorization from FDA to be legally marketed
`
`8
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 11 of 35 PageID# 30313
`
`PREMARKET APPLICATIONS
`
`• Applications for premarket review for certain deemed new tobacco products on the market
`as of Aug. 8, 2016, were required to be submitted to FDA by Sept. 9, 2020
`
`– Per a court ruling issued Aug. 19, 2020, FDA is not enforcing this requirement for premium cigars
`
`• FDA received applications for more than 6.5 million deemed new tobacco products,
`most of which were submitted very close to the Sept. 9 deadline
`
`• Most applications were premarket tobacco product applications (PMTAs) for ENDS
`products, like e-cigarettes, which had never previously been through the FDA review
`process
`
`9
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 12 of 35 PageID# 30314
`
`REVIEW OF PMTAS
`
`• FDA’s job is to assess the applicant’s scientific evidence to
`determine if the marketing of the tobacco product is
`“appropriate for the protection of the public health”
`
`• This means we have to assess the risks and benefits to the
`population as a whole, including:
`
`– Users and nonusers of the product under review
`
`– Whether people who currently use any tobacco product would stop
`
`– Whether nonusers would start
`
`10
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 13 of 35 PageID# 30315
`
`REVIEW PROGRESS
`
`• FDA has taken action on more than 98% of the over 6.5 million products in the timely
`submitted applications. As of Oct. 13, this includes:
`
`– Completing acceptance review for all applications submitted by the Sept. 9 deadline, which
`resulted in issuing refuse to accept (RTA) letters to more than 200,000 applications
`
`– Completing filing review for almost all timely submitted PMTAs, including issuing a refuse to file
`(RTF) letter to a single company for PMTAs associated with approximately 4.5 million products
`
`– Issuing Substantial Equivalence (SE) marketing orders covering more than 120 products
`
`– Issuing Exemption from SE marketing orders covering more than 230 products
`
`– Issuing marketing denial orders (MDOs) for more than 1 million non-tobacco flavored ENDS
`products
`
`– Issuing marketing granted orders for 3 new tobacco products
`
`11
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 14 of 35 PageID# 30316
`CONSIDERATIONS DURING REVIEW OF NON-TOBACCO
`FLAVORED ENDS PRODUCTS
`
`• Non-tobacco flavored ENDS products pose a known and significant risk with respect to
`youth appeal, uptake, and use
`
`• ENDS continue to be the most used type of tobacco product among youth
`
`– More than 80% of youth who use ENDS report using a flavored product—with fruit being the most
`reported flavor type overall, by school level, and across all e-cigarette devices
`
`– Youth ENDS users are more likely to use flavored ENDS compared with adult END users
`
`– Studies consistently show that flavors influence youth initiation of ENDS use
`
`12
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 15 of 35 PageID# 30317
`CONSIDERATIONS DURING REVIEW OF NON-TOBACCO
`FLAVORED ENDS PRODUCTS
`
`• Companies who want to continue to market their flavored ENDS
`products must have robust and reliable evidence showing
`that their products’ potential benefit for adult smokers outweighs
`the significant known risk to youth
`
`• By contrast, tobacco-flavored ENDS raise a different set of
`considerations because they do not pose the same degree of
`risk of youth uptake
`
`13
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 16 of 35 PageID# 30318
`AUTHORIZATION OF ENDS PRODUCTS THROUGH THE
`PMTA PATHWAY
`
`• On Oct. 12, FDA authorized the marketing of three new tobacco products, marking
`the first set of ENDS products ever to be authorized by FDA
`
`• R.J. Reynolds (RJR) Vapor Company submitted data that demonstrates its tobacco-
`flavored products could benefit addicted adult smokers who switch to these products—
`either completely or with a significant reduction in cigarette consumption—by reducing
`their exposure to harmful chemicals
`
`• Additionally, FDA considered the risks and benefits to the population as a whole and
`determined the potential benefits to smokers outweigh the risk to youth
`
`• FDA also issued 10 MDOs for RJR’s flavored Vuse Solo ENDS products
`
`14
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 17 of 35 PageID# 30319
`
`PMTA AUTHORIZATION: NEW ORAL TOBACCO PRODUCTS
`
`• On Oct. 19, FDA authorized the marketing of four oral tobacco products
`manufactured by U.S. Smokeless Tobacco Company LLC (USSTC) under the brand name
`of VERVE®
`
`• These are mint flavored products, containing nicotine, that are chewed and then discarded
`when the user is finished
`
`• The company submitted data that demonstrates these products could benefit addicted
`adult smokers who switch to them—either completely or with a significant reduction in
`cigarette consumption—by reducing their exposure to harmful chemicals
`
`• Additionally, research shows a low likelihood that youth, non-smokers, or former
`smokers would initiate or reinitiate tobacco use with these products
`
`15
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 18 of 35 PageID# 30320
`
`REMAINING PENDING APPLICATIONS
`
`• FDA continues to work expeditiously on the remaining applications that were submitted by
`the court’s Sept. 9, 2020, deadline, many of which are in the final stages of review
`
`– The agency has around 80,000 products pending that are the subject of timely submitted
`PMTAs
`
`• FDA continues to review PMTAs for non-tobacco flavored ENDS to determine whether
`there is sufficient product-specific scientific evidence of a benefit to adult smokers to
`overcome the risk posed to youth
`
`– The scientific review of menthol ENDS raises unique considerations, and FDA is reviewing
`every product on a case-by-case basis with the same review standards
`
`• FDA is also reviewing a smaller number of pending applications under the SE
`standard for cigars, pipes, and hookah tobacco
`
`16
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 19 of 35 PageID# 30321
`
`LEGAL CHALLENGES AND APPEALS
`
`• As of Oct. 26, 46 cases filed for judicial review of specific MDO actions (45 pending)
`
`• Dozens of requests for supervisory review of negative actions (under Title 21 of Code of
`Federal Regulations section 10.75)
`
`17
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 20 of 35 PageID# 30322
`
`COMPLIANCE AND ENFORCEMENT
`
`18
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 21 of 35 PageID# 30323
`
`FDA’S ENFORCEMENT PRIORITIES
`
`• All new tobacco products on the market without the statutorily required premarket
`authorization are marketed unlawfully and are subject to enforcement action at FDA’s
`discretion
`
`• As described in FDA’s enforcement guidance, we have identified flavored products that
`appeal to youth as enforcement priorities
`
`• Products for which no application is pending, including, for example, those with an
`MDO and those for which no application was submitted, are among our highest
`enforcement priorities
`
`19
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 22 of 35 PageID# 30324
`
`UPDATE ON COMPLIANCE AND ENFORCEMENT
`
`• FDA has been closely monitoring manufacturer, importer, and distributor
`compliance with the premarket authorization requirement
`
`• Since Jan. 2021, FDA has issued 173 warning letters to firms that
`collectively have listed more than 17 million ENDS products with FDA
`and did not submit premarket applications for these products
`
`• On Oct. 7, FDA issued warning letters to 22 companies for unlawfully
`marketing products that are subject to MDOs and/or RTF determinations
`on their premarket applications
`
`20
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 23 of 35 PageID# 30325
`
`RULES AND GUIDANCES
`
`21
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 24 of 35 PageID# 30326
`
`PMTA AND SE FINAL RULES
`
`• On Oct. 5, FDA published two final rules in the
`Federal Register for the premarket review of new
`tobacco products—and they are effective Nov. 4
`
`• These foundational rules provide additional information
`on the requirements for the content, format, and
`review of Premarket Tobacco Product Applications
`(PMTAs) and Substantial Equivalence (SE) Reports
`
`• Finalizing these rules helps ensure all future PMTAs and
`SE Reports contain the basic information FDA needs
`to determine whether the new tobacco products meet
`the relevant premarket requirements to efficiently and
`effectively implement the Tobacco Control Act
`
`22
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 25 of 35 PageID# 30327
`
`LOOKING AHEAD: PROPOSED PRODUCT STANDARDS
`
`•
`
`In April, FDA announced it is working toward issuing proposed
`product standards in Spring 2022. FDA plans to:
`– ban menthol as a characterizing flavor in cigarettes
`– ban all characterizing flavors in cigars
`• This decision is based on clear science and evidence
`establishing the addictiveness and harm of these products
`and builds on important, previous actions that banned other
`flavored cigarettes in 2009
`
`• These actions will help significantly reduce youth initiation,
`increase the chances of smoking cessation among current
`smokers, and address health disparities experienced by
`communities of color, low-income populations, and LGBTQ+
`individuals
`
`23
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 26 of 35 PageID# 30328
`
`PUBLIC EDUCATION CAMPAIGNS
`
`2424
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`
`
`CENTER FOR TOBACCO PRODUCTSCENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 27 of 35 PageID# 30329
`“THE REAL COST” YOUTH E-CIGARETTE USE PREVENTION
`CAMPAIGN
`
`• Since 2017, FDA’s award-winning public education
`campaign “The Real Cost” has been prioritizing e-
`cigarette prevention messaging to address alarming
`youth vaping rates
`
`•
`
`“The Real Cost” Youth E-Cigarette Prevention Campaign
`reaches youth aged 12 to 17 who have used e-
`cigarettes or are open to trying them
`
`• Campaign messages focus on educating youth that
`using e-cigarettes, just like cigarettes, puts them at risk
`for addiction and other health consequences
`
`25
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 28 of 35 PageID# 30330
`
`CAMPAIGN REACH
`
`• Since “The Real Cost” E-Cigarette Prevention effort launched, the campaign has shown
`effective reach and engagement results—reaching up to 85% of all teens nationwide
`through paid media messages
`
`• Across social media, FDA has engaged teen audiences with more than 3.9 million likes,
`more than 355,000 shares, and more than 90,000 comments—with 10% of comments
`coming from teens asking for help and resources to quit vaping
`
`• FDA also collaborated with the National Cancer Institute to develop vaping cessation
`content for teens on Teen.SmokeFree.gov
`
`– Since the content launched in 2019, there have been more than 2 million page views
`
`– Visitors spend an average of 4 minutes per page to learn how to quit vaping, manage nicotine
`withdrawal, and deal with stress and anxiety
`
`26
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 29 of 35 PageID# 30331
`
`A NEW CHALLENGE: SYNTHETIC NICOTINE
`
`27
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 30 of 35 PageID# 30332
`
`A RISE IN SYNTHETIC NICOTINE
`
`•
`
`Increasing number of ENDS products that use, or
`claim to use, synthetic nicotine instead of
`nicotine derived from tobacco
`
`– Includes Puff Bar, reported in the 2021 NYTS as the
`most popular brand among youth e-cigarette users
`
`• To try to avoid FDA regulation and evade
`enforcement, several companies that received
`MDOs are publicly saying they are switching to
`synthetic nicotine to keep their products on the
`market
`
`“
`
`VaporSalon is switching to
`TOBACCO FREE NICOTINE on
`Friday, 8/27/2021. … F*** the
`FDA and their over-reaching
`over-burdensome regulations
`that small businesses were never
`ever going to be successful in
`completing and they knew that
`from the start.
`
`”
`
`28
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 31 of 35 PageID# 30333
`
`KEY CHALLENGES WITH SYNTHETIC NICOTINE
`
`• The definition of “tobacco product” includes any product made or derived from
`tobacco, including a component, part, or accessory of a tobacco product
`
`• E-liquids that do not contain nicotine or other substances made or derived from tobacco
`may still be components or parts of tobacco products and, therefore, subject to
`FDA's tobacco control authorities
`
`• FDA intends to make these determinations on a case-by-case basis, based on the totality
`of the circumstances
`
`29
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 32 of 35 PageID# 30334
`
`KEY CHALLENGES WITH SYNTHETIC NICOTINE
`
`•
`
`It’s becoming more difficult to test and differentiate tobacco-derived nicotine from
`synthetic nicotine
`
`• Nicotine has two isomer forms (R- and S-nicotine)
`
`– Tobacco-derived nicotine is 99% S-nicotine
`
`– Previous synthetic nicotine formulations were 50/50 nicotine isomers
`
`– Newer synthetic nicotine formulations can consist of more than 99% S-nicotine
`
`• Tobacco-derived nicotine is now readily available as higher quality U.S. pharmaceutical-
`grade 99% nicotine, which no longer contains traditional tobacco agricultural markers
`like tobacco DNA or tobacco specific nitrosamines – making it harder to distinguish
`tobacco-derived nicotine from synthetic
`
`30
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 33 of 35 PageID# 30335
`
`FDA’S REGULATORY PATH FORWARD
`
`• FDA is very concerned about the implications of companies
`attempting to evade regulation by using synthetic nicotine,
`particularly as it regards to potential youth ENDS use
`
`•
`
`In the short term, the agency is exploring how to best address the
`growing number of products where the jurisdiction is under
`review due to the source of nicotine
`
`• FDA is also in discussions with Congress about a potential
`legislative fix
`
`31
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 34 of 35 PageID# 30336
`
`ADDITIONAL FDA PRESENTATION
`
`Matthew R. Holman, Ph.D., Director,
`
`Office of Science, Center for Tobacco Products
`
`1:30 – 2:40 p.m.
`
`- Panel coming up next after the break -
`
`Pre-Market Tobacco Applications (PMTAs):
`
`Recent Decisions and Surveying the Post-Deadline Landscape
`
`32
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1103-1 Filed 02/25/22 Page 35 of 35 PageID# 30337
`CONTACTING/FOLLOWING FDA’S CENTER FOR TOBACCO
`PRODUCTS
`
`• Report adverse experiences with tobacco products at:
`https://www.safetyreporting.hhs.gov
`
`• Call us: (877) CTP-1373
`
`• Email us: AskCTP@fda.hhs.gov
`
`• Follow us on Twitter: @FDATOBACCO
`
`33
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
